ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF
Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases,...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SMITH, Christopher Ronald CHAPMAN, Justin |
| description | Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes).
L'invention concerne des composés d'isoindolin-1-one pour traiter diverses maladies et pathologies. Plus particulièrement, la présente invention concerne l'utilisation d'un composé d'isoindolin-1-one ou d'analogues de celui-ci, dans le traitement de troubles caractérisés par l'activation d'ASK1 (par exemple, des maladies cardiovasculaires, des troubles inflammatoires (aigus ou chroniques), des maladies auto-immunes, des troubles osseux destructifs, des maladies/troubles fibrotiques tels que la stéatohépatite alcoolique; la stéatose hépatique nn alcoolique (NAFLD); la stéatohépatite non alcoolique (NASH), les troubles neurodégénératifs et les maladies métaboliques telles que le diabète). |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2020006429A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2020006429A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2020006429A13</originalsourceid><addsrcrecordid>eNrjZLB2DPY2VPAM9vf0c_H38fTTNdT193NV8PTz8HTyDPEPClZw9HNR8HUN8fB3CVbwd1MIDXZVCPFwDXL1d-NhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRgYGBmYmRpaOhsbEqQIAUaEpyg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF</title><source>esp@cenet</source><creator>SMITH, Christopher Ronald ; CHAPMAN, Justin</creator><creatorcontrib>SMITH, Christopher Ronald ; CHAPMAN, Justin</creatorcontrib><description>Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes).
L'invention concerne des composés d'isoindolin-1-one pour traiter diverses maladies et pathologies. Plus particulièrement, la présente invention concerne l'utilisation d'un composé d'isoindolin-1-one ou d'analogues de celui-ci, dans le traitement de troubles caractérisés par l'activation d'ASK1 (par exemple, des maladies cardiovasculaires, des troubles inflammatoires (aigus ou chroniques), des maladies auto-immunes, des troubles osseux destructifs, des maladies/troubles fibrotiques tels que la stéatohépatite alcoolique; la stéatose hépatique nn alcoolique (NAFLD); la stéatohépatite non alcoolique (NASH), les troubles neurodégénératifs et les maladies métaboliques telles que le diabète).</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200102&DB=EPODOC&CC=WO&NR=2020006429A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200102&DB=EPODOC&CC=WO&NR=2020006429A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SMITH, Christopher Ronald</creatorcontrib><creatorcontrib>CHAPMAN, Justin</creatorcontrib><title>ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF</title><description>Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes).
L'invention concerne des composés d'isoindolin-1-one pour traiter diverses maladies et pathologies. Plus particulièrement, la présente invention concerne l'utilisation d'un composé d'isoindolin-1-one ou d'analogues de celui-ci, dans le traitement de troubles caractérisés par l'activation d'ASK1 (par exemple, des maladies cardiovasculaires, des troubles inflammatoires (aigus ou chroniques), des maladies auto-immunes, des troubles osseux destructifs, des maladies/troubles fibrotiques tels que la stéatohépatite alcoolique; la stéatose hépatique nn alcoolique (NAFLD); la stéatohépatite non alcoolique (NASH), les troubles neurodégénératifs et les maladies métaboliques telles que le diabète).</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB2DPY2VPAM9vf0c_H38fTTNdT193NV8PTz8HTyDPEPClZw9HNR8HUN8fB3CVbwd1MIDXZVCPFwDXL1d-NhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRgYGBmYmRpaOhsbEqQIAUaEpyg</recordid><startdate>20200102</startdate><enddate>20200102</enddate><creator>SMITH, Christopher Ronald</creator><creator>CHAPMAN, Justin</creator><scope>EVB</scope></search><sort><creationdate>20200102</creationdate><title>ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF</title><author>SMITH, Christopher Ronald ; CHAPMAN, Justin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2020006429A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SMITH, Christopher Ronald</creatorcontrib><creatorcontrib>CHAPMAN, Justin</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SMITH, Christopher Ronald</au><au>CHAPMAN, Justin</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF</title><date>2020-01-02</date><risdate>2020</risdate><abstract>Isoindolin-1-one compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoindolin-1-one compound or analogs thereof, in the treatment of disorders characterized by the activation of ASK1 (e.g., cardiovascular diseases, inflammatory disorders (acute or chronic), autoimmune diseases, destructive bone disorders, fibrotic diseases/disorders such as alcoholic steatohepatitis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH), neurodegenerative disorders, and metabolic diseases such as diabetes).
L'invention concerne des composés d'isoindolin-1-one pour traiter diverses maladies et pathologies. Plus particulièrement, la présente invention concerne l'utilisation d'un composé d'isoindolin-1-one ou d'analogues de celui-ci, dans le traitement de troubles caractérisés par l'activation d'ASK1 (par exemple, des maladies cardiovasculaires, des troubles inflammatoires (aigus ou chroniques), des maladies auto-immunes, des troubles osseux destructifs, des maladies/troubles fibrotiques tels que la stéatohépatite alcoolique; la stéatose hépatique nn alcoolique (NAFLD); la stéatohépatite non alcoolique (NASH), les troubles neurodégénératifs et les maladies métaboliques telles que le diabète).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2020006429A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | ASK1 ISOINDOLIN-1-ONE INHIBITORS AND METHODS OF USE THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A53%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SMITH,%20Christopher%20Ronald&rft.date=2020-01-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2020006429A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |